2,471
Views
31
CrossRef citations to date
0
Altmetric
Research Article

Local release of gemcitabine via in situ UV-crosslinked lipid-strengthened hydrogel for inhibiting osteosarcoma

, , , , , & show all
Pages 1642-1651 | Received 10 May 2018, Accepted 02 Jul 2018, Published online: 27 Aug 2018

References

  • Arpicco SM, Rocco F, Brusa P. (2004). Cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. Cancer Treat Res 152:3.
  • Celano M, Calvagno MG, Bulotta S, et al. (2004). Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells. BMC Cancer 4:63.
  • Cheng H, Yue K, Kazemzadeh-Narbat M, et al. (2017). Mussel-inspired multifunctional hydrogel coating for prevention of infections and enhanced osteogenesis. ACS Appl Mater Interfaces 9:11428.
  • Christine E, Darlington ASE, Stride CB, et al. (2001). Quality of Life Implications as a Consequence of Surgery: Limb Salvage, Primary and Secondary Amputation. Sarcoma 5(4):189–95.
  • Czitrom AA, Langer F, Mckee N, et al. (1986). Bone and cartilage allotransplantation. A review of 14 years of research and clinical studies. Clin Orthop Relat R 208:141.
  • Deng W, Yamaguchi H, Takashima Y, et al. (2007). A chemical-responsive supramolecular hydrogel from modified cyclodextrins. Angew Chem 119:5236–9.
  • Dou XQ, Yang XM, Li P, et al. (2012). Novel pH responsive hydrogels for controlled cell adhesion and triggered surface detachment. Soft Matter 8:9539–44.
  • Dou XQ, Zhang D, Feng CL. (2013). Wettability of supramolecular nanofibers for controlled cell adhesion and proliferation. Langmuir 29:15359.
  • Fuchs B, Pritchard DJ. (2002). Etiology of osteosarcoma. Clin Orthop Relat Res 397:40–52.
  • Gaetano BMD, Alessandra LMD, Michela VMA, et al. (2006). Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Cancer 106:1154–61.
  • Immordino ML, Brusa P, Rocco F, et al. (2004). Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. J Control Release 100:331–46.
  • Kabata T, Tsuchiya H, Sakurakichi K, et al. (2005). Reconstruction with distraction osteogenesis for juxta-articular nonunions with bone loss. J Trauma 58:1213–22.
  • Limb CJ, Long DM, Niparko JK. (2005). Acoustic neuromas after failed radiation therapy: challenges of surgical salvage. Laryngoscope 115:93.
  • Liotta LA, Steeg PS, Stetler-Stevenson WG. (1991). Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64:327–36.
  • Longhi A, Errani C, De Paolis M, et al., (2006). Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 32:423–36.
  • Molina I, Li S, Martinez MB, et al. (2001). Protein release from physically crosslinked hydrogels of the PLA/PEO/PLA triblock copolymer-type. Biomaterials 22:363–9.
  • Morrow GR. (1985). The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy. Cancer 55:2766–70.
  • Noshadi I, Hong S, Sullivan KE, et al. (2017). In vitro and in vivo analysis of visible light crosslinkable gelatin methacryloyl (GelMA) hydrogels. Biomater Sci 5:2093.
  • Ottaviani G, Jaffe N. (2009). The epidemiology of osteosarcoma. Cancer Treat Res 152:3.
  • Panda JJ, Dua R, Mishra A, et al. (2010). 3D cell growth and proliferation on a RGD functionalized nanofibrillar hydrogel based on a conformationally restricted residue containing dipeptide. ACS Appl Mater Interfaces 2:2839–48.
  • Paolino D, Cosco D, Racanicchi L, et al. (2010). Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity. J Control Release 144:144–50.
  • Popescu RC, Andronescu E, Vasile BŞ, et al. (2017). Fabrication and cytotoxicity of gemcitabine-functionalized magnetite nanoparticles. Molecules 22:1080.
  • Rasalkar DD, Chu WC, Lee V, et al. (2011). Pulmonary metastases in children with osteosarcoma: characteristics and impact on patient survival. Pediatr Radiol 41:227–36.
  • Roberts P, Chan D, Grimer RJ, et al. (1991). Prosthetic replacement of the distal femur for primary bone tumours. J Bone Joint Surg BR 73:762–9.
  • Rytting M, Pearson P, Raymond AK, et al. (2000). Osteosarcoma in preadolescent patients. Clin Orthop Relat Res 373:39–50.
  • Strauss SJ, Ng T, Mendoza-Naranjo A, et al. (2010). Understanding micrometastatic disease and anoikis resistance in ewing family of tumors and osteosarcoma. Oncologist 15:627.
  • Ta HT, Dass CR, Choong PF, et al. (2009). Osteosarcoma treatment: state of the art. Cancer Metastasis Rev 28:247–63.
  • Tao H, Chen F, Liu H, et al. (2017). Wnt/β-catenin signaling pathway activation reverses gemcitabine resistance by attenuating Beclin1-mediated autophagy in the MG63 human osteosarcoma cell line. Mol Med Rep 16:1701.
  • Wang C, Zhang G, Liu G, et al. (2017). Photo- and thermo-responsive multicompartment hydrogels for synergistic delivery of gemcitabine and doxorubicin. J Control Release 259:149–59.
  • Wu W, Ni Q, Xiang Y, et al. (2016). Fabrication of a photo-crosslinked gelatin hydrogel for preventing abdominal adhesion. RSC Adv 6:92449.
  • Wu X, Cai ZD, Chen ZR, et al. (2012). A preliminary evaluation of limb salvage surgery for osteosarcoma around knee joint. PLoS One 7:e33492.
  • Xin T, Gu Y, Cheng R, et al. (2017). Inorganic strengthened hydrogel membrane as regenerative periosteum. ACS Appl Mater Interfaces 9:41168.
  • Yazar S, Lin CH, Wei FC. (2004). One-stage reconstruction of composite bone and soft-tissue defects in traumatic lower extremities. Plast Reconstr Surg 114:1457.
  • Yeo Y, Geng W, Ito T, et al. (2007). Photocrosslinkable hydrogel for myocyte cell culture and injection. J Biomed Mater Res Part B Appl Biomater 81:312–22.
  • Yue K, Santiago GT, Alvarez MM, et al. (2015). Synthesis, properties, and biomedical applications of gelatin methacryloyl (GelMA) hydrogels. Biomaterials 73:254–71.